BiotechTube
Home/Foghorn Therapeutics/Adrian Gottschalk
AG

Adrian Gottschalk

President and Chief Executive Officer

Foghorn Therapeutics

Therapeutic Areas

Oncology

Foghorn Therapeutics Pipeline

DrugIndicationPhase
FHD-286Relapsed/Refractory Acute Myeloid Leukemia (AML)Phase 1
FHD-609Synovial SarcomaPhase 1
FHD-909Indication TBD (BRM-selective inhibitor)Phase 1

Leadership Team at Foghorn Therapeutics

SB
Steven Bellon
Chief Scientific Officer
CC
Carlos Costa
Chief People Officer
DD
Danette Daniels
Vice President, Protein Degrader Platform
View full Foghorn Therapeutics profile